Abstract
Concurrent chemoradiation is often chosen for advanced head and neck cancer. Especially, concurrent chemoradiation is effective for oropharyngeal cancer. Single-agent cisplatin (CDDP) is often used in concurrent chemoradiation, and the usual method of radiation is conventional fractionation. A comparative study with conventional fractionated radiotherapy showed that hyperfractionated radiotherapy improves survival rates. We have tried weekly CDDP concurrent chemo-hyperfractionated radiotherapy to decrease the degree of toxic issues. Although the clinical study of weekly CDDP concurrent chemo-hyperfractionated radiotherapy is still ongoing, complete response has been observed in 3 of 5 cases, and G3/G4 toxic issues are myelosuppression, mucositis oral, laryngitis, weight loss, and nutrition disorders.
